175 related articles for article (PubMed ID: 36245736)
1. Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort.
Yang L; Tang Y; He F; Zhang C; Kessi M; Peng J; Yin F
Front Pediatr; 2022; 10():996213. PubMed ID: 36245736
[TBL] [Abstract][Full Text] [Related]
2. Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis.
Yan C; Li W; Song J; Feng X; Xi J; Lu J; Zhou S; Zhao C
Pediatr Neurol; 2019 Sep; 98():74-79. PubMed ID: 31307830
[TBL] [Abstract][Full Text] [Related]
3. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
4. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
[TBL] [Abstract][Full Text] [Related]
5. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
6. [Childhood-onset myasthenia gravis: the analysis of influencing factors of therapeutic effect and prognosis].
Qin NN; Chen RL; Ma S; Zhang XJ; Sun HL; Jing Y
Zhonghua Er Ke Za Zhi; 2011 May; 49(5):371-5. PubMed ID: 21624290
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.
Huang Q; Li F; Zhao S
BMC Neurol; 2022 Mar; 22(1):73. PubMed ID: 35246057
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of 424 childhood-onset myasthenia gravis patients.
Gui M; Luo X; Lin J; Li Y; Zhang M; Zhang X; Yang M; Wang W; Bu B
J Neurol; 2015; 262(4):823-30. PubMed ID: 25588729
[TBL] [Abstract][Full Text] [Related]
9. An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis.
Motobayashi M; Inaba Y; Nishimura T; Kobayashi N; Nakazawa Y; Koike K
Pediatr Neurol; 2015 Apr; 52(4):404-9. PubMed ID: 25661289
[TBL] [Abstract][Full Text] [Related]
10. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors for the prognosis of myasthenia gravis.
Wang L; Zhang Y; He M
BMC Neurol; 2017 Apr; 17(1):77. PubMed ID: 28420327
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.
Mee J; Paine M; Byrne E; King J; Reardon K; O'Day J
J Neuroophthalmol; 2003 Dec; 23(4):251-5. PubMed ID: 14663303
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
[TBL] [Abstract][Full Text] [Related]
15. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
[TBL] [Abstract][Full Text] [Related]
16. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Mullaney P; Vajsar J; Smith R; Buncic JR
Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.
Huang X; Li Y; Feng H; Chen P; Liu W
Front Neurol; 2018; 9():77. PubMed ID: 29535672
[TBL] [Abstract][Full Text] [Related]
18. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort.
Popperud TH; Boldingh MI; Rasmussen M; Kerty E
Eur J Paediatr Neurol; 2017 Sep; 21(5):707-714. PubMed ID: 28457757
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
